Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof

Abstract

The present invention provides methods and apparatuses for detecting, measuring, or locating cells or substances present in even very low concentrations in vivo in subjects, using targeted magnetic nanoparticles and special magnetic systems. The magnetic systems can comprise magnetizing subsystems and sensors subsystems, including as examples SQUID sensors and atomic magnetometers. The magnetic systems can detect, measure, or location particles bound by antibodies to cells or substances of predetermined types. Example magnetic systems are capable of detecting sub-nanogram amounts of these nanoparticles.

What is claimed is: 
     
         1 . An apparatus for the detection, measurement, or location of one or more predetermined types of cancer cells or biologic substances in vivo, comprising:
 (a) a magnetizing subsystem, configured to magnetize superparamagnetic nanoparticles that are bound to one or more predetermined types of cancer cells or biologic substances in a patient, where the nanoparticles are bound to cancer cells or biologic substances by an antibody or peptide; and   (b) a sensor subsystem, configured to detect a residual magnetic field in a region of the patient during a time after the net magnetic moments of nanoparticles not bound to cancer cells or biologic substances have decayed and before magnetic moments of nanoparticles bound cancer cells or biologic substances have decayed, and   (c) an analysis subsystem configured to analyze the residual magnetic field to detect, measure, or locate the one or more predetermined types of cancer cells or biologic substances in a patient.   
     
     
         2 . An apparatus as in  claim 1 , wherein the nanoparticles are bound to cancer cells or biologic substances by an antibody. 
     
     
         3 . An apparatus as in  claim 2 , wherein the nanoparticles are bound to prostate cancer cells by prostate-specific membrane antigen. 
     
     
         4 . An apparatus as in  claim 2 , wherein the nanoparticles are bound to cancer cells by Her2/neu antibody. 
     
     
         5 . An apparatus as in  claim 2 , wherein the nanoparticles are bound to ovarian cancer cells by CA125 antibody. 
     
     
         6 . An apparatus as in  claim 2 , wherein the nanoparticles are bound to lymphoma cells by CD15 antibody, CD30 antibody, CD25 antibody, or a combination of the preceding. 
     
     
         7 . An apparatus as in  claim 2 , wherein the nanoparticles are bound to glioblastoma cells by EGFR, 81C6, PTN, or a combination of the preceding. 
     
     
         8 . An apparatus as in  claim 2 , wherein the nanoparticles are bound to pancreatic cancer cells by uPAR antibody. 
     
     
         9 . An apparatus as in  claim 2 , wherein the nanoparticles are bound to cancer cells or biologic substances by a peptide. 
     
     
         10 . A method to detect, measure, or locate one or more predetermined types of cancer cells or biologic substances in vivo, comprising:
 (a) providing an apparatus as in  claim 1 ;   (b) placing a plurality of targeted nanoparticles into a patient, wherein each of the plurality of targeted nanoparticles comprises a superparamagnetic nanoparticle conjugated with a targeting agent that preferentially binds with one or more predetermined types of cancer cells or biologic substances;   (c) using the magnetizing subsystem to magnetize the nanoparticles;   (d) using the sensor subsystem to determine a residual magnetic field in a region of the patient during a time after the net magnetic moments of nanoparticles not bound to cancer cells or biologic substances have decayed and before magnetic moments of nanoparticles bound cancer cells or biologic substances have decayed, and   (c) using the analysis subsystem to analyze the residual magnetic field to detect, measure, or locate one or more predetermined types of cancer cells or biologic substances.   
     
     
         11 . An apparatus as in  claim 1 , wherein the targeting agent comprises an antibody. 
     
     
         12 . An apparatus as in  claim 2 , wherein the targeting agent comprises a prostate-specific membrane antigen. 
     
     
         13 . An apparatus as in  claim 2 , wherein the targeting agent comprises a Her2/neu antibody. 
     
     
         14 . An apparatus as in  claim 2 , wherein the targeting agent comprises a CA125 antibody. 
     
     
         15 . An apparatus as in  claim 2 , wherein the targeting agent comprises a CD15 antibody, CD30 antibody, CD25 antibody, or a combination of the preceding. 
     
     
         16 . An apparatus as in  claim 2 , wherein the targeting agent comprises a EGFR, 81C6, PTN, or a combination of the preceding. 
     
     
         17 . An apparatus as in  claim 2 , wherein the targeting agent comprises a uPAR antibody. 
     
     
         18 . An apparatus as in  claim 2 , wherein the targeting agent comprises a peptide.